Hims & Hers Plunges 15% as Novo Nordisk Surges on Wegovy Momentum
Hims & Hers shares plunged 15% while Novo Nordisk stock surged on investor rotation toward its Wegovy franchise. The intensifying battle for the weight-loss drug market around Wegovy is reshaping revenue forecasts and valuation for Novo Nordisk.
1. Stock Movements
Hims & Hers shares dropped 15% as investors shunned its virtual weight-management offerings, reallocating capital into Novo Nordisk, whose stock surged on renewed confidence in its Wegovy weight-loss drug.
2. Weight-Loss Market Shift
Wegovy’s expanding indications and accelerating prescription growth have solidified Novo Nordisk’s leadership in the estimated $12 billion U.S. weight-loss drug segment, prompting analysts to lift full-year revenue and margin projections for the company.
Related News
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
GS
Goldman Sachs Warns of Record 8.7M bpd Oil Draws, Inventories at Eight-Year Low
GS•
ING
ING-backed euro stablecoin consortium grows to 37 banks, eyes H2 launch
ING•
PERI
Perion Q1 Revenue Rises 1% as Outmax AI Spend Soars 300% and CTV Spend Jumps 68%
PERI•
Sources
F